Clinically and ethically relevant questions are related to patient safety, therapeutic efficacy, equitable access, and global governance over humanity’s genetic legacy.
AMA J Ethics. 2019;21(12):E1079-1088. doi:
10.1001/amajethics.2019.1079.
Gene editing reminds professionals and the public that this technology’s reach goes beyond treating somatic disease to germline consequences yet unknown.
AMA J Ethics. 2019;21(12):E1056-1058. doi:
10.1001/amajethics.2019.1056.
Dr Dónal O’Mathúna joins Ethics Talk to discuss his article, coauthored with Dr Nawaraj Upadhaya: “Should Children Be Enrolled in Clinical Research in Conflict Zones?”
Gene editing to enhance humans’ adaptability to climate change should consider safety, harm to be averted, succeeding generations, and social consequences.
AMA J Ethics. 2017;19(12):1186-1192. doi:
10.1001/journalofethics.2017.19.12.stas1-1712.
The Holocaust and the racial hygiene doctrine that helped rationalize it still overshadow contemporary debates about using gene editing for disease prevention.
AMA J Ethics. 2021;23(1):E49-54. doi:
10.1001/amajethics.2021.49.
Dania Pagarkar joins Ethics Talk to discuss her article, coauthored with Drs Erin Harrop and Lisa Erlanger: “How Should We Approach Body Size Diversity in Clinical Trials?”